SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Elvis Presley Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientElvis Presley
Date of birth1935-01-08
IdentifiersMRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417
Document date2026-11-01
AuthorColeman Ashby-Nakagawa, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral. Concerns: He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need; He has put on weight and feels bloated and constipated, and is self-conscious about it on stage; He wants to stop needing so many pills without going through withdrawal or missing a show. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultationUp to five tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultationUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a timeOne tablet three times daily; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a timeUp to three tablets a day; seven-day supplyOral route1974-07-10 to 1974-07-17completedS
Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucomaStoppedOral route1974-07-10 to 1974-07-10completedS
Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologistOne drop in each eye at bedtimeOphthalmic route1974-07-10activeS
Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bagOne spray for a suspected overdose; call 911Nasal route1974-07-10activeS
Polyethylene glycol 3350, 17 g powder in a glass of water once daily17 g in water once dailyOral route1974-07-10activeS
Senna 8.6 mg oral tablet, two tablets at bedtimeTwo tablets at bedtimeOral route1974-07-10 to 1974-08-07completedS
Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic onlyTwo films once daily, or one film twice dailySublingual route1974-07-17activeS
Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stableOne tablet four times daily; seven-day supplyOral route1974-07-17 to 1974-08-07completedS
Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a timeOne tablet three times daily with the 2 mg tablets as scheduledOral route1974-08-07activeS
Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg)Per the written taper scheduleOral route1974-08-07 to 1974-10-28completedS
Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet dailyOne tablet dailyOral route1974-07-17activeS
Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly2.5 mg once weeklySubcutaneous route1974-08-07 to 1974-09-23completedS
Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly5 mg once weeklySubcutaneous route1974-09-23activeS
Naproxen 500 mg oral tablet, one tablet twice daily with food for five daysOne tablet twice daily with food for five daysOral route1974-09-09 to 1974-09-13completedS

Procedures

ProcedureDatesStatusEvidence
Twelve-lead electrocardiogram at the evaluation of high blood pressure readings, before any change in his medicines: sinus rhythm at 92, normal axis, no left ventricular hypertrophy, QTc 436 ms1974-07-10 to 1974-07-10completedS
Attended in-laboratory split-night polysomnography (chosen over home testing because he takes opioids and benzodiazepines): apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80%; CPAP titrated to 11 cm H2O, which controlled events1974-07-14 to 1974-07-14completedS
Advance care planning conversation, about 20 minutes1974-08-14 to 1974-08-14completedS

Immunizations

DateVaccineStatusEvidence
1974-08-14Tdap vaccine; last tetanus booster more than ten years agocompletedS
1974-09-23Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunitycompletedS
1974-10-28Hepatitis B vaccine (HepB-CpG), second of two dosescompletedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

Historical dateHistoryEvidence
1971Glaucoma, with an acute angle-closure episode treated years earlier; under an ophthalmologist's care sinceD (CLM-0007)
October 15, 1973Hospital stay of about two weeks in which, by later testimony, he was withdrawn from narcotic drugs; recorded without detailD (CLM-0003)

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows needactiveS
He has put on weight and feels bloated and constipated, and is self-conscious about it on stageactiveS
He wants to stop needing so many pills without going through withdrawal or missing a showactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 15.1 on 1974-07-10; Sodium [Moles/volume] in Serum or Plasma 139 on 1974-07-10; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1974-10-28; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 1974-10-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M 96 on 1974-10-28; Glucose [Mass/volume] in Serum or Plasma 104 on 1974-07-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 1974-10-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 44 on 1974-10-28; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 1974-10-28; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 55 on 1974-10-28; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 1974-07-10; Albumin/Creatinine [Mass Ratio] in Urine 14 on 1974-07-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1974-10-28; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1974-10-28; Total score [DAST-10] 7 on 1974-07-10; Total score [AUDIT-C] 0 on 1974-07-10; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1974-08-14; Cholesterol in HDL [Mass/volume] in Serum or Plasma 38 on 1974-08-14; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 140 on 1974-08-14; Triglyceride [Mass/volume] in Serum or Plasma 180 on 1974-08-14 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readingsresolvedconfirmed R53.83S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses.
Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped workingactiveconfirmed E66.811S — Synthetic modern diagnosis anchored to his documented weight gain.
Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoidedactiveconfirmed H40.63X1S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes.
Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillersactiveconfirmed F11.20S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis.
Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedativesactiveconfirmed F13.20S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis.
Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normalactiveconfirmed I10S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension.
Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAPactiveconfirmed G47.33S — Synthetic modern diagnosis from a synthetic sleep study.
Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm featuresactiveconfirmed K59.03S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon.
Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolvedresolvedconfirmed S39.012AS — Synthetic acute injury; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1974-07-10Hemoglobin [Mass/volume] in Blood15.1g/dL13.2-17.1 g/dLNormalS
1974-07-10Sodium [Moles/volume] in Serum or Plasma139mmol/L135-145 mmol/LNormalS
1974-07-10Potassium [Moles/volume] in Serum or Plasma4mmol/L3.5-5.1 mmol/LNormalS
1974-07-10Creatinine [Mass/volume] in Serum or Plasma1mg/dL0.74-1.35 mg/dLNormalS
1974-07-10Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M98mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1974-07-10Glucose [Mass/volume] in Serum or Plasma104mg/dL70-99 mg/dLHighS
1974-07-10Hemoglobin A1c/Hemoglobin.total in Blood5.8%<=5.6%HighS
1974-07-10Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma72U/L7-55 U/LHighS
1974-07-10Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma52U/L8-48 U/LHighS
1974-07-10Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma78U/L8-61 U/LHighS
1974-07-10Thyrotropin [Units/volume] in Serum or Plasma2.1m[IU]/L0.4-4.5 mIU/LNormalS
1974-07-10Albumin/Creatinine [Mass Ratio] in Urine14mg/g{creat}<=29 mg/g{creat}NormalS
1974-07-10Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]8{score}S
1974-07-10Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]9{score}S
1974-07-10Total score [DAST-10]7{score}S
1974-07-10Total score [AUDIT-C]0{score}S
1974-08-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1974-08-14Cholesterol [Mass/volume] in Serum or Plasma214mg/dL<=199 mg/dLHighS
1974-08-14Cholesterol in HDL [Mass/volume] in Serum or Plasma38mg/dL>=40 mg/dLLowS
1974-08-14Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation140mg/dL<=129 mg/dLHighS
1974-08-14Triglyceride [Mass/volume] in Serum or Plasma180mg/dL<=149 mg/dLHighS
1974-08-07Potassium [Moles/volume] in Serum or Plasma4.4mmol/L3.5-5.1 mmol/LNormalS
1974-08-07Creatinine [Mass/volume] in Serum or Plasma1.04mg/dL0.74-1.35 mg/dLNormalS
1974-08-07Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M94mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1974-08-07Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]6{score}S
1974-08-07Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]8{score}S
1974-09-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1974-09-23Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]7{score}S
1974-10-28Potassium [Moles/volume] in Serum or Plasma4.3mmol/L3.5-5.1 mmol/LNormalS
1974-10-28Creatinine [Mass/volume] in Serum or Plasma1.02mg/dL0.74-1.35 mg/dLNormalS
1974-10-28Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M96mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1974-10-28Hemoglobin A1c/Hemoglobin.total in Blood5.5%<=5.6%NormalS
1974-10-28Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma44U/L7-55 U/LNormalS
1974-10-28Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma33U/L8-48 U/LNormalS
1974-10-28Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma55U/L8-61 U/LNormalS
1974-10-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1974-10-28Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Social History

Vital Signs

DateMeasureValueUnitProvenance
1974-07-10Body height183cmS
1974-07-10Body weight109kgS
1974-07-10Body mass index (BMI) [Ratio]32.5kg/m2S
1974-07-10Systolic blood pressure154mm[Hg]S
1974-07-10Diastolic blood pressure98mm[Hg]S
1974-07-10Heart rate94/minS
1974-07-10Respiratory rate16/minS
1974-07-10Body temperature36.8CelS
1974-07-10Oxygen saturation in Arterial blood by Pulse oximetry96%S
1974-07-17Body height183cmS
1974-07-17Body weight108.6kgS
1974-07-17Body mass index (BMI) [Ratio]32.4kg/m2S
1974-07-17Systolic blood pressure146mm[Hg]S
1974-07-17Diastolic blood pressure94mm[Hg]S
1974-07-17Heart rate102/minS
1974-07-17Respiratory rate18/minS
1974-07-17Body temperature37CelS
1974-07-17Oxygen saturation in Arterial blood by Pulse oximetry96%S
1974-08-07Body height183cmS
1974-08-07Body weight108.2kgS
1974-08-07Body mass index (BMI) [Ratio]32.3kg/m2S
1974-08-07Systolic blood pressure128mm[Hg]S
1974-08-07Diastolic blood pressure82mm[Hg]S
1974-08-07Heart rate76/minS
1974-08-07Respiratory rate14/minS
1974-08-07Body temperature36.7CelS
1974-08-07Oxygen saturation in Arterial blood by Pulse oximetry97%S
1974-09-23Body height183cmS
1974-09-23Body weight105.1kgS
1974-09-23Body mass index (BMI) [Ratio]31.4kg/m2S
1974-09-23Systolic blood pressure126mm[Hg]S
1974-09-23Diastolic blood pressure80mm[Hg]S
1974-09-23Heart rate74/minS
1974-09-23Respiratory rate14/minS
1974-09-23Body temperature36.6CelS
1974-09-23Oxygen saturation in Arterial blood by Pulse oximetry97%S
1974-10-28Body height183cmS
1974-10-28Body weight102.6kgS
1974-10-28Body mass index (BMI) [Ratio]30.6kg/m2S
1974-10-28Systolic blood pressure122mm[Hg]S
1974-10-28Diastolic blood pressure78mm[Hg]S
1974-10-28Heart rate70/minS
1974-10-28Respiratory rate14/minS
1974-10-28Body temperature36.6CelS
1974-10-28Oxygen saturation in Arterial blood by Pulse oximetry98%S
1974-08-14Body height183cmS
1974-08-14Body weight107.6kgS
1974-08-14Body mass index (BMI) [Ratio]32.1kg/m2S
1974-08-14Systolic blood pressure126mm[Hg]S
1974-08-14Diastolic blood pressure80mm[Hg]S
1974-08-14Heart rate74/minS
1974-08-14Respiratory rate14/minS
1974-08-14Body temperature36.6CelS
1974-08-14Oxygen saturation in Arterial blood by Pulse oximetry97%S
1974-09-09Body height183cmS
1974-09-09Body weight106kgS
1974-09-09Body mass index (BMI) [Ratio]31.7kg/m2S
1974-09-09Systolic blood pressure134mm[Hg]S
1974-09-09Diastolic blood pressure84mm[Hg]S
1974-09-09Heart rate84/minS
1974-09-09Respiratory rate16/minS
1974-09-09Body temperature36.7CelS
1974-09-09Oxygen saturation in Arterial blood by Pulse oximetry97%S

Encounters

DatePurposeStatusProvenance
1974-07-10Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referralfinishedS
1974-07-17One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure resultsfinishedS
1974-08-07Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagementfinishedS
1974-09-23Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tourfinishedS
1974-10-28Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan aheadfinishedS
1974-08-14Periodic adult preventive visitfinishedS
1974-09-09Same-day sick visit for low back painfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptlycompletedGL-CDC-OPIOID-2022, GL-CDC-PDMP, GL-BZD-TAPER-2025S
Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and tapercompletedGL-ASAM-OUD-2020, GL-BZD-TAPER-2025S
Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explainedcompletedGL-CDC-OPIOID-2022, GL-ASAM-OUD-2020S
Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each reviewcompletedGL-SUICIDE-2024, GL-USPSTF-DEP-2023, GL-CMID-2026S
Buprenorphine for opioid use disorder: buprenorphine with naloxone started in the office at a COWS score above 8, 16 mg a day, weekly contact for the first month, prescriptions from this clinic only, counseling, and no tapering off while he is doing well; buprenorphine is not withheld because he takes a benzodiazepinecompletedGL-ASAM-OUD-2020, GL-CDC-OPIOID-2022S
Benzodiazepine change and taper: alprazolam combined into diazepam (40 mg a day), held steady until buprenorphine is stable, then reduced by about 5 to 10% every two to four weeks, paused during engagements, illness or withdrawal symptoms, never stopped abruptly; CBT for anxiety and insomnia alongside; no Z-drug or other sedative in its placecompletedGL-BZD-TAPER-2025S
Hypertension: home readings confirmed stage 2 hypertension, so two first-line drugs were started in one pill (amlodipine with valsartan), with potassium and creatinine two to four weeks later, a target below 130/80, sodium reduction, activity and weight losscompletedGL-AHA-HTN-2025, GL-CMID-2026S
Obstructive sleep apnea: CPAP from the split-night titration, with adherence data reviewed at each visit and a travel machine for tours; no sedative added at nightcompletedGL-AASM-PAP-2019, GL-AASM-DX-2017S
Weight treated without stigma: earlier meals, protein and fiber, more walking and karate between tours, and tirzepatide once weekly, chosen because it also treats obstructive sleep apnea with obesity, raised slowly with a watch on nausea and constipationcompletedGL-AGA-OBESITY-2022, GL-SURMOUNT-OSA-2024S
Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomitingcompletedGL-AGA-OIC-2019, GL-AGA-ACG-CIC-2023S
Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with haloscompletedGL-AAO-POAG-2020, GL-CMID-2026S
Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venuescompletedGL-ASAM-OUD-2020, GL-BZD-TAPER-2025S

Goals

GoalTargetStatusOutcomeProvenance
Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal1974-08-07completedBuprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings lowS
One prescriber and one pharmacy for all controlled medicines1974-09-23completedMonitoring program shows only this clinic's prescriptions since intakeS
Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping1974-10-28active40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuingS
Home blood pressure below 130/801974-08-07completedHome average 146/94 to 126/80 on amlodipine and valsartanS
Lose 5% or more of body weight1974-10-28completed109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier mealsS
CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness1974-10-28completedCPAP on 88% of nights; Epworth 14 to 6S
A bowel movement at least every two days without straining1974-08-07completedEvery one to two days on buprenorphine and polyethylene glycolS

Functional Status

Mental Status

Structured synthetic safety assessment on 1974-07-10: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. No current or past suicidal ideation. Risk factors reviewed: opioid and sedative use disorders under assessment, taking opioids with benzodiazepines, sleep apnea symptoms, firearms at home, and the stress of touring. Means safety: firearms to be stored locked and unloaded with ammunition separate; all controlled medicines in a locked box, with unused tablets from earlier prescriptions taken back to a pharmacy; seven-day supplies; naloxone at home and in the tour bag, with two people around him taught to use it. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]